VAGELOS P ROY - 16 Dec 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/** P. Roy Vagelos
Issuer symbol
REGN
Transactions as of
16 Dec 2021
Net transactions value
-$80,008
Form type
4
Filing time
20 Dec 2021, 15:13:47 UTC
Previous filing
10 Dec 2021
Next filing
15 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities $12,059 -19 -0.86% $634.70 2,202 16 Dec 2021 By 401(k) Plan
transaction REGN Common Stock Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities $67,948 -107 -4.9% $635.03 2,095 16 Dec 2021 By 401(k) Plan F1
holding REGN Common Stock 318,669 16 Dec 2021 Direct
holding REGN Common Stock 141,630 16 Dec 2021 by CLAT
holding REGN Common Stock 37,747 16 Dec 2021 by Spouse as Trustee
holding REGN Common Stock 3,609 16 Dec 2021 by trust for grandch F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents volume-weighted average price of sales of 107 shares of Company stock on December 16, 2021 at prices ranging from $635.00 to $635.06. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 16, 2021 at each separate price.
F2 By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.